Focus: Ochre Bio is a UK-based biotechnology company focused on siRNA liver drugs for gene therapy and oncology indications. The company operates as a pre-revenue biotech with a specialized focus on RNA therapeutics targeting hepatic diseases.
Profile data last refreshed 44m ago · AI intelligence enriched 2w ago
Ochre Bio is a high-risk, early-stage RNA therapeutics platform play best suited for scientists seeking foundational roles in an emerging modality, not stability or near-term career momentum.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ochre Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ochre Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo